Innate Pharma to Attend Jefferies and Goldman Sachs Healthcare Investor Gatherings
Innate Pharma Q1 2025 Earnings Call Set for May 13
Innate Pharma, a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients, has announced the date for its Q1 2025 Earnings Call. The call is scheduled for May 13, 2025, at 8:00 AM ET.
During the call, key executives, including Henry Wheeler, VP of IR and Communications, and Jonathan Dickinson, CEO, will participate and represent the company.
Innate Pharma's executive team will also participate and represent the Company during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 to June 3, 2025.
Aside from the Q1 Earnings Call, the company's executive team is set to participate in two upcoming investor conferences. They will attend the Jefferies Global Healthcare Conference on June 5, 2025, and the Goldman Sachs 46 Annual Global Healthcare Conference on June 10, 2025.
Innate Pharma's portfolio includes several ANKET drug candidates for multiple tumor types. Notably, the company is developing lacutamab, an anti-KIR3DL2 mAb for advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas. They are also working on IPH4502, a differentiated ADC for solid tumors.
Monalizumab, an anti-NKG2A mAb, is developed with AstraZeneca for non-small cell lung cancer. This innovative approach involves three therapeutic approaches: multi-specific NK Cell Engagers, Antibody Drug Conjugates, and monoclonal antibodies.
Innate Pharma's shares are listed on Euronext Paris and Nasdaq in the US. The ISIN code for Innate Pharma shares is FR0010331421, and the Nasdaq ticker code is IPHA, while the Euronext ticker code is IPH. The LEI code for Innate Pharma is 9695002Y8420ZB8HJE29.
This press release does not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. The Company's forward-looking statements are subject to numerous risks and uncertainties. These risks and uncertainties include, but are not limited to, the uncertainties inherent in research and development, regulatory approvals, commercialization efforts, and the Company's ability to raise capital. The Company does not undertake to publicly update any forward-looking statements, except as required by law.
For media inquiries, please contact Arthur Rouillé at +33 (0)1 44 71 00 15 or [email protected]. For additional information about Innate Pharma, please contact Henry Wheeler at +33 (0)4 84 90 32 88 or [email protected].
[1] Source: Business Wire [2] Source: Champalimaud Foundation (unrelated company) [3] Source: Festival of Biologics [4] Source: NextGen Biomed 2025
- The cloud of news surrounding Innate Pharma continues to grow as they announce their Q1 2025 Earnings Call on May 13.
- In the realm of health-and-wellness and medical-conditions, Innate Pharma is developing various therapies-and-treatments, including lacutamab and IPH4502.
- The financial industry will be keenly watching Innate Pharma's performance, as they attend several business events such as the Jefferies Global Healthcare Conference and Goldman Sachs' annual event.4.Sequences in the field of science, particularly in immunotherapy for cancer, will be discussed during the upcoming ASCO Annual Meeting by the company's executive team.
- As Innate Pharma's shareholders and the general public eagerly await the Q1 Earnings Call, it's crucial to remember the company's forward-looking statements are subject to numerous risks and uncertainties.
